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Introduction and Objective
• Background: regaining strength through subacute 
rehabilitation (SAR) as a mechanism to return cancer 
patients to therapy is poorly understood
• Rationale: provide realistic advice to patients when 
cancer-directed therapy must be stopped
• Inquiry question: what are cancer patients able to 
accomplish following referral to SAR?
• Hypothesis: majority of patients will not return to 
cancer-directed therapy following SAR; high functional 
status at discharge will be the best predictor of return
Methods
• Population: metastatic solid tumor patients discharged to 
SAR (2018-2020)
• Partnership: Neu Center Research Team
• Collection methods: retrospective chart review
• Main predictors & outcomes:
• Primary outcome = patient return to anti-cancer therapy
• Main predictor = PT functional status score (AMPAC)
• Analysis: descriptive statistics of patient outcomes + 
logistic regression of AMPAC score and return to therapy
Results
• Results are pending!
• Example results:
Only 31 of the 112 patients (28%) returned to cancer-
directed therapy within 60 days of discharge to SAR. 
Functional status score was positively associated with 
return to cancer-directed therapy. The average survival for 
patients was 36 days from original discharge and 40% of 
patients were readmitted to the hospital within 30 days.
Conclusions
• Potential impact: guidance to patients during difficult 
turning point in care
• Limitations: sample only includes SKCC patients, decision is 
highly individual
• Next steps: receive data through EPIC extraction → run 
analysis with statistician → assist in writing paper
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